Indoco Remedies Ltd Q2 FY26 Earnings Analysis

- The Company expects noticeable growth in sterile product supply to the US from Q3 FY '26 onwards following US FDA approval to restart two lines (Page 13). - European sales are anticipated to bounce back to regular levels by Q3 FY '26 after overcoming supply challenges (Page 8). - Domestic business showed 10% growth in IQVIA secondary sales with healthy double-digit growth in key segments; expectations are stable or improving (Page 9). - OTC business grew over 46% sequentially and is expected to break even in a couple of years with enhanced marketing investments (Page 12). - Semi-regulated markets show good growth driven by brand-building and revamped sales strategy, expected to sustain (Page 8). - International business showed 26% increase in solid oral exports in Q1 FY '26, indicating positive momentum (Page 4). - Incremental efficiency and cost control measures underway suggest improving margins alongside revenue growth (Page 9).

- The company aims to return to EBITDA margins of around 11%-13% (levels seen pre-remediation issues), with quarter-on-quarter improvement expected. - Efforts in cost containment, controlling other expenses, and optimizing CAPEX are underway to improve profitability. - Management expects sustained growth in international and domestic markets, with Europe supply resuming fully by Q3 and improvement in semi-regulated markets due to brand building. - OTC business is still in investment phase but showed EBITDA break-even in Q1, with expectations to breakeven fully in a couple of years. - US market revenue ramp-up is anticipated possibly from Q4 FY '26, after pending FDA inspections and remediation. - R&D expenses will be maintained around 5%-5.5% of revenues, with 4-5 filings expected in FY '26 to drive future growth. - Debt reduction plans include Rs. 68 crore repayment over next 9 months, improving financial health and interest cost management.

- Current CAPEX is being controlled carefully as per management. - Ongoing projects at Goa Plant-2 and the API site for Warren Remedies are underway. - Gradual completion of these projects is expected, but not entirely within this year. - Incremental CAPEX for the current year is not expected to exceed around Rs. 50 crore. - No mention of new or additional strategic investments beyond controlling existing capital expenditure.

- No explicit mention of any new fundraising through debt or equity in the current quarter or immediate future. - Capital expenditure is being carefully controlled, with only around Rs. 50 crore expected to be spent this year on ongoing projects, indicating no major expansion needing fresh funds. - Warren Remedies, which has a negative net worth of Rs. 52 crore, is expected to receive capital infusion in the coming three quarters to strengthen its balance sheet. - No capital infusion required for the US subsidiary FPP Holdings, as profitability is expected to improve. - Debt repayments planned: about Rs. 68 crore over the next nine months, indicating focus on reducing existing debt rather than raising new debt. - Overall, the company appears focused on debt reduction and prudent CAPEX, with no new large fundraising planned currently.

- As per the transcript, Indoco Remedies is currently ramping up manufacturing activities after receiving US FDA approval to restart two lines; however, sales from these sterile products are yet to happen. - Full efficiency and rollout of plants, especially post-remediation, are expected by end of Q2 FY '26, with all plants fully operational by Q3 FY '26. - The balancing of products and the right number of orders are still being established following last year’s supply disturbances. - Europe supply challenges are expected to be overcome by end of Q2 FY '26, with a bounce back in Q3. - The US sterile product supply, including complex ophthalmic products like Brinzolamide, is anticipated to potentially start showing revenue impact from Q3 or Q4 FY '26. - No explicit numerical orderbook or pending order values were disclosed in the call transcript.